Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Characterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study.

Haessler F, Gaese F, Huss M, Kretschmar C, Brinkman M, Peters H, Elstner S, Colla M, Pittrow D.

BMC Psychiatry. 2016 Sep 10;16(1):318. doi: 10.1186/s12888-016-1020-5.

2.

Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry.

Stangel M, Gold R, Pittrow D, Baumann U, Borte M, Fasshauer M, Hensel M, Huscher D, Reiser M, Sommer C.

Ther Adv Neurol Disord. 2016 May;9(3):165-79. doi: 10.1177/1756285616629869. Epub 2016 Feb 16.

3.

Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk.

Laufs U, Karmann B, Pittrow D.

Clin Res Cardiol. 2016 Sep;105(9):783-90. doi: 10.1007/s00392-016-0991-z. Epub 2016 Apr 27.

4.

Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias.

Hoeper MM, Behr J, Held M, Grunig E, Vizza CD, Vonk-Noordegraaf A, Lange TJ, Claussen M, Grohé C, Klose H, Olsson KM, Zelniker T, Neurohr C, Distler O, Wirtz H, Opitz C, Huscher D, Pittrow D, Gibbs JS.

PLoS One. 2015 Dec 2;10(12):e0141911. doi: 10.1371/journal.pone.0141911. eCollection 2015.

5.

Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.

Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, Andreas S, Claussen M, Grohé C, Wilkens H, Randerath W, Skowasch D, Meyer FJ, Kirschner J, Gläser S, Herth FJ, Welte T, Huber RM, Neurohr C, Schwaiblmair M, Kohlhäufl M, Höffken G, Held M, Koch A, Bahmer T, Pittrow D.

Eur Respir J. 2015 Jul;46(1):186-96. doi: 10.1183/09031936.00217614. Epub 2015 Apr 2.

6.

One-year safety and quality of life outcomes in patients with atrial fibrillation on dronedarone: prospective, non-interventional study in German ambulatory care.

Goette A, Benninger G, Pittrow D, Paar WD, von Stritzky B, Bosch RF.

Herzschrittmacherther Elektrophysiol. 2015 Jun;26(2):148-54. doi: 10.1007/s00399-015-0360-z. Epub 2015 Mar 8.

7.

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry.

Behr J, Hoeper MM, Kreuter M, Klotsche J, Wirtz H, Pittrow D.

BMJ Open Respir Res. 2014 Jan 3;1(1):e000010. doi: 10.1136/bmjresp-2013-000010. eCollection 2014. Erratum in: BMJ Open Respir Res. 2014;1(1):e000010corr1.

8.

Demographics, clinical characteristics, health resource utilization and cost of chronic thromboembolic pulmonary hypertension patients: retrospective results from six European countries.

Schweikert B, Pittrow D, Vizza CD, Pepke-Zaba J, Hoeper MM, Gabriel A, Berg J, Sikirica M.

BMC Health Serv Res. 2014 Jun 9;14:246. doi: 10.1186/1472-6963-14-246.

9.

Improved detection of paroxysmal atrial fibrillation utilizing a software-assisted electrocardiogram approach.

Schaefer JR, Leussler D, Rosin L, Pittrow D, Hepp T.

PLoS One. 2014 Feb 28;9(2):e89328. doi: 10.1371/journal.pone.0089328. eCollection 2014.

10.

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.

Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fischer A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigris J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim DS, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR; CTD-ILD Special Interest Group..

Thorax. 2014 May;69(5):428-36. doi: 10.1136/thoraxjnl-2013-204202. Epub 2013 Dec 24. Erratum in: Thorax. 2014 Sep;69(9):834. CTD-ILD Special Interest Group [added]; multiple investigator names added.

11.

EXPLAIN Fragile-X: an explorative, longitudinal study on the characterization, treatment pathways, and patient-related outcomes of Fragile X Syndrome.

Haessler F, Gaese F, Colla M, Huss M, Kretschmar C, Brinkman M, Schieb H, Peters H, Elstner S, Pittrow D.

BMC Psychiatry. 2013 Dec 19;13:339. doi: 10.1186/1471-244X-13-339.

12.

Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry.

Schaefer JR, Gitt AK, Sonntag F, Weizel A, Jannowitz C, Karmann B, Pittrow D, Bestehorn K.

Vasc Health Risk Manag. 2013;9:71-80. doi: 10.2147/VHRM.S37143. Epub 2013 Feb 21.

13.

Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50.000 primary care patients.

Labeit AM, Klotsche J, Pieper L, Pittrow D, Einsle F, Stalla GK, Lehnert H, Silber S, Zeiher AM, März W, Wehling M, Wittchen HU.

PLoS One. 2012;7(12):e52229. doi: 10.1371/journal.pone.0052229. Epub 2012 Dec 28.

14.

Aliskiren/amlodipine as a single-pill combination in hypertensive patients: subgroup analysis of elderly patients, with metabolic risk factors or high body mass index.

Axthelm C, Sieder C, Meister F, Pittrow D, Kaiser E.

J Drug Assess. 2012 Dec 25;2(1):1-10. doi: 10.3109/21556660.2012.762367. eCollection 2013.

15.

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed.

Denton CP, Avouac J, Behrens F, Furst DE, Foeldvari I, Humbert M, Huscher D, Kowal-Bielecka O, Matucci-Cerinic M, Nash P, Opitz CF, Pittrow D, Rubin LJ, Seibold JR, Distler O.

Arthritis Res Ther. 2011 Jun 20;13(3):114. doi: 10.1186/ar3346.

16.

Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry.

Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P; ATRIUM investigators..

Clin Res Cardiol. 2011 Oct;100(10):897-905. doi: 10.1007/s00392-011-0320-5. Epub 2011 May 1.

18.
19.

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

Opitz CF, Ewert R, Kirch W, Pittrow D.

Eur Heart J. 2008 Aug;29(16):1936-48. doi: 10.1093/eurheartj/ehn234. Epub 2008 Jun 17. Review.

20.

Profound influence of different methods for determination of the ankle brachial index on the prevalence estimate of peripheral arterial disease.

Lange SF, Trampisch HJ, Pittrow D, Darius H, Mahn M, Allenberg JR, Tepohl G, Haberl RL, Diehm C; getABI Study Group..

BMC Public Health. 2007;7:147.

Supplemental Content

Loading ...
Support Center